WHO vaccine-preventable diseases: monitoring system. 2017 global summary

Last updated 15-July-2017 (data as of 11-July-2017)
Next overall update Fall-2017
EPI mother and child logo         
Select a country

Development status: Developing GNI / capita (US$): 21'3101 Infant (under 12 months) mortality rate: 102
GDP / capita (US$): 23'7951 Child (under 5 years) mortality rate: 122

Population data in thousands3

  2016  2015  2014  2013  2012  2000  1990  1980 
Total population 391  387  382  377  372  298  256  211 
Births
Surviving infants
Pop. less than 5 years 28  28  28  28  28  28  28  25 
Pop. less than 15 years 80  80  80  80  81  87  83  78 
Female 15-49 years 106  106  105  105  104  84  70  55 

Number of reported cases

(Click for retrospective incidence data for Bahamas (the))
Diphtheria
ChartChart
 
Japanese encephalitis
 
Measles
ChartChart ChartChart
  72  484 
Mumps
ChartChart
 
Pertussis
ChartChart
  15 
Polio*
ChartChart
 
Rubella
ChartChart
 
Rubella (CRS)
ChartChart
 
Tetanus (neonatal)
ChartChart
 
Tetanus (total)**
ChartChart
 
Yellow fever
 
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For disaggregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Bahamas (the))
Vaccine year result method % card seen                                                
BCG         
DTP1          95  99*  96  99*  99  99* 
DTP3          94  95  96  97  98  99  87  36 
DTP4          84  91  74 
IPV1          95  31 
HepB_BD         
HepB3          94  95  96  97  96 
Hib3          94  95  96  97  98  90 
JapEnc         
MCV1          89  94  92  92  91  93  99 
MCV2          74  76  72  69  73 
MenA         
PCV1          95  99*  96  99*  77 
PCV2          94  93  94  99*  46 
PCV3          94  95  96  97  37 
Pol3          94  95  96  97  99  91  82  35 
Rota1          11  12 
RotaC          11  10  10 
RCV1          89  94  92  92  91 
TT2plus          99  99*  99  98  97 
PAB          99*  98  97 
VAD1         
YFV         
* indicates the country reported above 100% coverage.

  Next update: Mid-July 2018

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Bahamas (the))
DTP1
ChartChart
  95  99  96  99  99  99  95  61 
DTP3
ChartChart
  94  95  96  97  98  99  86  36 
HepB3
ChartChart
  94  95  96  97  96 
HepB_BD
ChartChart
 
Hib3
ChartChart
  94  95  96  97  98  90 
IPV1
  95  31 
MCV1
ChartChart
  89  94  92  92  91  93  86 
MCV2
ChartChart
  74  76  72  69  73 
PCV3
ChartChart
  94  95  96  97  37 
Pol3
ChartChart
  94  95  96  97  99  91  82  35 
RCV1
ChartChart
  89  94  92  92  91  93 
RotaC
 

Click for WHO-UNICEF coverage estimates data for PAB time series.

Number of districts in the country 16  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
 
   
/
|
|
\
Greater or equal to 90% 63
From 80 to 89% 6
From 50 to 79% 13
Less than 50% 13
Proportion of districts
not reporting DTP3 coverage
5
DTP3 reported coverageDTP3 reported coverage

Immunization Schedule (2016 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
DTaPHibHepIPV 2, 4, 6 months; No
DTaPHibIPV 2, 4, 6 months; No
DTwP 4-5 years; Yes
DTwPHib 15 months; Yes
DTwPHibHepB 2, 4, 6 months; Yes
HPV 9-15 years;
Influenza_Adult Yes elderly, adults with chronic diseases, and pregnant women, health care workers
Influenza_Pediatric 6-35 months; Yes and children with chronic disease
IPV 2, 4 months; Yes
MMR 1, 4-5 years; Yes
OPV 6 months; Yes
Pneumo_conj 2, 4, 6, 15 months; Yes
Rotavirus 2, 4, 6 months; Yes
Td 10-12 years; Yes every 10 years
Tdap 10-12 years; Yes every 10 years
Varicella 1, 4-5 years; Yes

Immunizaton indicators

Indicator Expected answer 2016  2015  2014  2013  2012  2011  2010 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 
What years does the MYP cover? number 2010-2020  2010-2020  2010-2020  2010-2020  2010-2020  2010-2015  2010-2012 
Nº of districts with microplans that include activities to raise immunization coverage number  

System performance

Total Nº districts in country number 16  16  16  45  91  91  31 
Nº districts with DTP3 coverage >=80% number 11  15  16  44  91  23   
% of districts with DTP3 coverage >=80% From 0 to 100% 69  94  100  98  100  25   
Nº districts with measles (MCV1) coverage >=95% number 10  30  35  23   
% of districts with MCV1 coverage >=95% From 0 to 100% 50  50  63  67  38  25   

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND Yes  Yes  No  No  No  No  No 
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Finance

% of Immunization expenditure financed, using Government funds? From 0 to 100%   100  99  100  100     

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR No  No  No  No  No  No  No 

Sources

 1  "The 2017 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2016, data for 2015
 3  "United Nations, Population Division. The World Population Prospects - the 2017 revision". New York, 2017.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.